Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system.
The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. The software automatically adjusts insulin delivery based on data received from the glucose monitor and the insulin pump.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics inks artificial pancreas deal with Roche, TypeZero Technologies appeared first on MassDevice.
from MassDevice http://ift.tt/2tzalGL
Cap comentari:
Publica un comentari a l'entrada